# A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

> **NCT06016088** · PHASE1,PHASE2 · RECRUITING · sponsor: **Respirion Pharmaceuticals Pty Ltd** · enrollment: 72 (estimated)

## Conditions studied

- Cystic Fibrosis Lung
- Respiratory Infections, Recurrent, Chronic
- Pseudomonas Aeruginosa

## Interventions

- **DRUG:** RSP-1502
- **DRUG:** Tobramycin inhalation solution

## Key facts

- **NCT ID:** NCT06016088
- **Lead sponsor:** Respirion Pharmaceuticals Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2026-04
- **Final completion:** 2026-06
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2025-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06016088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06016088, "A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06016088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*